Research Topics
| Rene GonzalezSummaryAffiliation: University of Colorado Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanomaSanjiv S Agarwala
Melanoma Center, University of Pittsburgh Cancer Institute, 200 Lothrop Street, Pittsburgh, PA 15213 2582, USA
J Clin Oncol 20:125-33. 2002..This study was designed to determine whether the addition of histamine to a subcutaneous (SC) regimen of interleukin-2 (IL-2) would improve the survival of metastatic melanoma patients...
Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case reportGuillermo A Escobar
Department of Surgery, Division of GI, Tumor and Endocrine Surgery, University of Colorado Health Sciences Center, 4200 E, 9th Ave, Denver, CO 80262, USA
BMC Cancer 7:13. 2007..It tends to present in large or metastatic tumors, and can appear at any time in the progression of the disease. We present herein a case of NICTH in a GIST tumor and report an exon 9 mutation associated to it...- Phase 2 trial of Allovectin-7 in advanced metastatic melanomaRene Gonzalez
University of Colorado Cancer Center, Aurora, CO 80010 5010, USA
Melanoma Res 16:521-6. 2006..8 months median duration of response. Allovectin-7 was shown to be safe and exhibit biological activity at this dose. Its safety profile may enable Allovectin-7 to be used at higher doses, which may provide greater clinical activity... 
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomesNicole Kounalakis
Division of GI, Tumor and Endocrine Surgery, University of Colorado Medical Center, Aurora, CO, USA
Immunotherapy 4:679-86. 2012..Completion lymph node dissection (CLND) and adjuvant therapy are recommended for node-positive melanoma patients. We sought to analyze our institution's experience with neoadjuvant biochemotherapy in stage III patients...- Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanomaKarl D Lewis
University of Colorado Health Sciences Center, Aurora, CO, USA
J Clin Oncol 24:3157-63. 2006..Toxicity of the biochemotherapy was high but generally manageable. CONCLUSION: The current study has expanded the preliminary evidence on neoadjuvant biochemotherapy for stage III melanoma... - A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanomaKarl D Lewis
University of Colorado Health Sciences Center, Aurora, CO, USA
Invest New Drugs 29:161-6. 2011..YM155 is a small molecule suppressant of survivin that has been shown in preclinical cell lines, xenograft models and phase I studies to have anti-tumor activity... - Immunologic therapy targeting metastatic melanoma: allovectin-7Rozina Chowdhery
University of Colorado Cancer Center, Anshutz Cancer Pavilion, PO Box 6510, Mail Stop F 703, Aurora, CO 80045, USA
Immunotherapy 3:17-21. 2011..Currently, a Phase III trial has completed enrollment and is set to determine the safety and efficacy of treatment in comparison with standard chemotherapy... - ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targetsYuchun Luo
Department of Dermatology, University of Colorado Denver, Aurora, Colorado 80045, USA
Stem Cells 30:2100-13. 2012..Further investigation of these isozymes and genes will enhance our understanding of the molecular mechanisms governing CSCs and reveal new molecular targets for therapeutic intervention of cancer... - Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local controlMichelle A Stinauer
University of Colorado Denver, School of Medicine, Aurora, Colorado, USA
Radiat Oncol 6:34. 2011..Whereas stereotactic body radiation therapy (SBRT) involves radiation dose intensification via escalation, we hypothesize SBRT might result in similar high local control rates as previously published on metastases of varying histologies... - Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literatureMayumi Fujita
Department of Dermatology and Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80010 7163, USA
Int J Dermatol 48:426-30. 2009..The development of vitiligo has been associated with an improved clinical response in melanoma patients... - ABT-737 synergizes with Bortezomib to kill melanoma cellsSteven N Reuland
University of Colorado Denver, School of Medicine, Department of Dermatology, Aurora, CO 80045, USA
Biol Open 1:92-100. 2012..These data imply that less toxic drugs fulfilling a function similar to Bortezomib to neutralize Mcl-1 are promising candidates for combination with ABT-737 for treating melanomas... - Novel therapies in melanomaBenjamin Scheier
Box B177, 1665 Aurora Court, Aurora, Colorado 80045, USA
Immunotherapy 3:1461-9. 2011.... - Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanomaMichael Bergen
University of Colorado Cancer Center, Anschutz Cancer Pavilion, PO Box 6510, Mail Stop F 703, Aurora, Colorado 80010, USA
Expert Opin Biol Ther 3:377-84. 2003..Ongoing trials are further investigating potential clinical uses of Allovectin-7... - Increased survival from stage IV melanoma associated with fewer regulatory T CellsJoel M Baumgartner
Department of Surgery, University of Colorado Denver, Denver, Colorado 80262, USA
J Surg Res 154:13-20. 2009..In this study, markers of immune escape including regulatory T cells (T(regs)), dendritic cells (DCs), and TGF-beta were evaluated in 14 Stage IV melanoma patients and correlated with survival... - Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patientsMartin D McCarter
Department of Surgery, University of Colorado at Denver Health Sciences Center, Denver, CO 80262, USA
Ann Surg Oncol 14:2854-60. 2007..Regulatory T cells (T(regs)) and plasmacytoid subpopulations of dendritic cells (pDCs) inhibit the immune response. We hypothesize that melanoma upregulates T(regs )and subpopulations of immunosuppressive dendritic cells (DCs)... - Size of sentinel node metastases predicts other nodal disease and survival in malignant melanomaNathan W Pearlman
Department of Surgery, University of Colorado Health Science, C311, University Hospital, 4200 E Ninth Avenue, Denver, CO 80262, USA
Am J Surg 192:878-81. 2006..We hypothesized SLN metastatic size of < or =2 mm would predict CLND status and prognosis... - Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistanceYuchun Luo
Department of Dermatology, University of Colorado Denver, Aurora, Colorado 80045, USA
J Invest Dermatol 132:2440-50. 2012..To our knowledge, this is a previously unreported study to isolate SP cells from melanoma patients and to investigate the gene expression profiling of these cells... - A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanomaKarl D Lewis
Cutaneous Oncology Program, University of Colorado Health Sciences Center, PO Box 6510, Mail Stop F703, Aurora, CO 80045, USA
Invest New Drugs 26:89-94. 2008..Although the current study did not meet the primary end-point of progression free survival of >or=20%, there is some evidence of activity and further investigation is warranted... - A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSFKarl D Lewis
University of Colorado Cancer Center, Aurora, Colorado, USA
Cancer Invest 23:303-8. 2005..6 months. Further studies of this novel biochemotherapy regimen are not indicated. Other schedules that incorporate temozolomide and/or GM-CSF and further studies to define the optimal method of delivering IL-2 should be pursued... - PI-88: a novel inhibitor of angiogenesisRagini Kudchadkar
University of Colorado Cancer Center, Aurora, CO 80045, USA
Expert Opin Investig Drugs 17:1769-76. 2008..However, the development of antibody-induced thrombocytopenia has limited its use in some patients... - Metastatic malignant melanoma from an unknown primary presenting as a large axillary massKarl D Lewis
Division of Medical Oncology, Cutaneous Oncology Program, University of Colorado Cancer Center, Denver, Colorado, USA
Oncology (Williston Park) 20:763-70. 2006 - A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanomaKarl D Lewis
University of Colorado, Cancer Center, 1665 North Ursula St, Mail Stop F-703, Aurora, CO 80045, USA
Invest New Drugs 24:89-94. 2006..In conclusion, Apomine, at the current dose studied, failed to produce a 30% progression free survival rate at 16 weeks considered to be a meaningful benefit for further development... - Therapeutic options in cutaneous melanoma: latest developmentsRodabe N Amaria
Department of Hematology Oncology, University of Colorado at Denver, Aurora, Colorado, USA
Ther Adv Med Oncol 3:245-51. 2011..Thus, this is a new era in the management of melanoma and we review the recent progress made in treating patients with advanced disease... - A case of Merkel cell carcinomaRagini Kudchadkar
Department of Cutaneous Oncology, University of Colorado at Denver Health Sciences Center, Aurora, Colorado 80045, USA
Oncology (Williston Park) 22:322-8. 2008 - A phase II study of Irofulven (MGI 114) in patients with stage IV melanomaA Scott Pierson
University of Colorado Cancer Center, Division of Medical Oncology, Anshutz Cancer Pavilion, Aurora 80010 0510, USA
Invest New Drugs 20:357-62. 2002..Based upon these data, Irofulven does not demonstrate significant antitumor activity to warrant further investigation in advanced melanoma... - A young woman with melanoma diagnosed during pregnancyKarl D Lewis
Oncology (Williston Park) 18:794-9. 2004 - Identifying risk factors for complications following sentinel lymph node biopsy for melanomaJ Brent Roaten
Department of Surgery and Medical Oncology, University of Colorado Health Sciences Center, Denver 80220, USA
Arch Surg 140:85-9. 2005..Experience with SLNBX decreases complications. Patients with more than 1 sentinel lymph node excised or a closed-suction drain placed at the time of SLNBX are at an increased risk of complications... - A phase II study of neoadjuvant biochemotherapy for stage III melanomaPeter Gibbs
Oncology Department, Royal Melbourne Hospital, Parkville, Victoria, Australia
Cancer 94:470-6. 2002..6%) remained free of disease progression. CONCLUSIONS: Neoadjuvant biochemotherapy appears to have promising activity in patients with Stage III melanoma. A larger multicenter study currently is underway to explore this approach further... - Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescentsJ Brent Roaten
Department of Surgery, University of Colorado Health Science Center, Denver, CO 80262, USA
J Pediatr Surg 40:232-5. 2005..Long-term follow-up data are needed before SLNBX can become a standard of care in pediatric melanoma or as a diagnostic tool to distinguish the atypical Spitz nevus from melanoma... - Survival in sentinel lymph node-positive pediatric melanomaJ Brent Roaten
Department of Surgery, University of Colorado Health Science Center, Denver, CO 80262, USA
J Pediatr Surg 40:988-92; discussion 992. 2005..Sentinel lymph node status does not predict early recurrence in pediatric patients with melanoma or atypical Spitz nevi... - Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trialKazuo Koyanagi
Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA 90404, USA
J Clin Oncol 23:8057-64. 2005..6; 95% CI, 3.16 to 50.5; P = .0003). CONCLUSION: Serial monitoring of CTCs in blood may be useful for indicating systemic subclinical disease and predicting outcome of patients receiving neoadjuvant BC for metastatic melanoma... - Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanomaRobert W Weber
Northern California Melanoma Center, Saint Francis Memorial Hospital, 900 Hyde St, San Francisco, CA 94109, USA
J Clin Oncol 23:8992-9000. 2005..Furthermore, it may protect against the development of brain metastases... - Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patientsKazuo Koyanagi
Department of Molecular Oncology, John Wayne Cancer Institute at Saint John s Health Center, Santa Monica, CA 90404, USA
Clin Cancer Res 12:1137-43. 2006.... - Metastatic melanoma in the breast: a report of 27 casesLarisa Ravdel
Division of Medical Oncology, University of Colorado Health Science Center, Denver, Colorado 80262, USA
J Surg Oncol 94:101-4. 2006..9 months. CONCLUSIONS: Metastases to the breast from melanoma are uncommon but should be suspected in patients with a breast mass and a prior history of melanoma even years after a primary has been removed... - Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study GroupDavid F McDermott
Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, East KS 159, Boston, MA, USA
J Clin Oncol 26:2178-85. 2008..This phase II study evaluated the efficacy and safety of sorafenib plus dacarbazine in patients with advanced melanoma... - Lymphangiomatosis masquerading as metastatic melanomaWilliam Qutub
Department of Surgery, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
Am Surg 72:367-70. 2006..Diagnosis and management of lymphangiomatosis is clinically challenging. This report reviews the literature on the pathology, diagnostic imaging, and management of lymphangiomatosis...